Benefit of treatment of latent tuberculosis infection in individual patients.

about

Benefit of treatment of latent tuberculosis infection in individual patients.

Item

http://www.wikidata.org/entity/Q42364683

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Benefit of treatment of latent tuberculosis infection in individual patients.

@en

Benefit of treatment of latent tuberculosis infection in individual patients.

@nl

type

Item

label

Benefit of treatment of latent tuberculosis infection in individual patients.

@en

Benefit of treatment of latent tuberculosis infection in individual patients.

@nl

prefLabel

Benefit of treatment of latent tuberculosis infection in individual patients.

@en

Benefit of treatment of latent tuberculosis infection in individual patients.

@nl

P1476

Benefit of treatment of latent tuberculosis infection in individual patients.

@en

P2093

Kyle Fluegge

http://www.w3.org/2001/XMLSchema#string

P2860

Tuberculosis elimination: theory and practice in Europe.

Towards tuberculosis elimination: an action framework for low-incidence countries

Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy

Assessing the impact of patient self-selection on the costs to treat latent tuberculosis infection (LTBI) with isoniazid and transitional rifampin.

Using Spatial Disease Patterns and Patient-Level Characteristics to Describe Prevalence Elastic Behavior in Treatment for Latent Tuberculosis Infection (LTBI).

Benefit of treatment of latent tuberculosis infection in individual patients.

A comparative effectiveness analysis of treatment for latent tuberculosis infection using multilevel selection models.

Genetic polymorphisms, drug metabolism and drug concentrations.

Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist?

P304

1592-1594

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1183/13993003.01946-2015

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kyle Fluegge

P577

2016-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27132272

http://www.w3.org/2001/XMLSchema#string

P932

5119636

http://www.w3.org/2001/XMLSchema#string